Explore Stanford technologies available for licensing:

Researchers at Stanford have identified the use of the drug verteporfin to treat or reduce the risk of developing ibrosis after ocular procedures or ocular injury. Of interest is corneal injury, for example after refractive surgery or crosslinking, e.g.

Stanford scientists have developed a new, better binder for the tumor-associated macrophage marker CD206. This binder can be conjugated to a variety of payloads, including an anti-immune checkpoint protein antibody for more selective immune checkpoint blockade.

The DeSimone Research Group at Stanford University developed a method for fabricating 3D pyrolytic carbon structures from polyacrylonitrile (PAN) generated by a scalable Vat Polymerization 3D-printing continuous liquid interface production (CLIP) process.

Researchers at Stanford and UCSF have determined methods of performing cell-free RNA (cfRNA) transcriptomics and metabolomics on urine samples.

Researchers at Stanford have developed an inducible and programmable CRISPR-mediated transcript organization (CRISPR-TO) method for repositioning RNAs to various desired subcellular compartments.

A team of Stanford researchers has developed humanized and chimeric mouse anti-human CD99 monoclonal antibodies with demonstrated activity against AML (acute myeloid leukemia) cells in vitro and in vivo.

Introduction: Blood cell transfusion plays a vital role in modern medicine–supporting surgery, obstetrics, trauma care, and cancer chemotherapy. In the US alone, more than 12 million red-cell units are consumed annually.

Non-alcoholic steatohepatitis (NASH) is the most common liver disease, leading to cirrhosis and hepatocellular carcinoma (HCC). HCC is one of the most common cancers and has a dismal prognosis as currently available medical treatment only improves survival by a few months.

Stanford scientists have discovered that a subset of human cathepsins can degrade cancer-associated mucins.

Researchers at Stanford University have developed a method which integrates cell barcoding and high-throughput sequencing to quantify tumor growth in genetically engineered mouse models of human cancer (called 'Tuba-seq” for Tumor barcoding coupled with seq

Technology Reference: Chan Zuckerberg CZB-190S; Stanford S20-449

Summary
Researchers at Stanford have developed a method enabling quantification of intracellular protein levels using oligonucleotide-barcoded antibodies.

Stanford scientists have created software, referred to as Symbolica, for automating model development for multiscale systems that can accelerate the generation of multi-physical models by 10^5 times what can be completed by hand.

Researchers at Stanford have identified GPR84 as a new highly specific imaging biomarker of neuroinflammation and innate immune activation.

Researchers at Stanford have proposed that coating surgical sutures with mechanotransduction inhibitors may reduce scarring of the tissue.

Stanford scientists have invented protein degraders that induce lysosomal degradation of extracellular cargo.